Drug Shortages Mostly FDA’s Fault, House Oversight Committee Concludes
This article was originally published in The Pink Sheet Daily
Report says aggressive enforcement in recent years has forced capacity offline, which led to shortages.
You may also be interested in...
With full NDA and BLA submissions to FDA now growing faster than INDs and supplements, user fees are increasing more rapidly as well.
FDA's grace period for transaction information sharing means that distribution channels will operate more smoothly, but also could result in more missed deadlines down the road.
Oversight and Investigations Subcommittee Chairman Murphy wants to know if FDA is aware of consequences of publishing letters during stock trading hours. The Energy and Commerce Committee examines whether FDA use of untitled letters is “fair, effective and efficient in gaining compliance,” he says.